Business Context and Reporting Period
This Form 8-K was filed by Mast Therapeutics, Inc. (not Savara Inc.) on September 28, 2015. The report details the entry into a material definitive agreement involving an amendment to an existing loan facility and the receipt of additional funding.
Key Financial Metrics and Debt
- Debt Facility: Total facility size is $15 million.
- Recent Funding: Received a "Second Advance" of $10 million on September 28, 2015.
- Prior Funding: $5 million was previously funded on August 11, 2015.
- Facility Charge: Paid an additional $37,500 in connection with the amendment.
- Equity Obligation: Warrant exercisable for up to 1,524,390 shares of common stock at an exercise price of $0.41 per share.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, or margins.
Material Changes Versus Prior Period
The primary material change is the amendment of the Loan and Security Agreement dated August 11, 2015. Previously, the $10 million Second Advance was contingent on achieving specific clinical and financial milestones by December 31, 2015. The amendment removed these conditions, allowing the Company to draw the funds immediately. Additionally, the warrant issued to the lender was amended to increase the number of exercisable shares by 243,903.
Outlook, Risks, and Contingencies
- Repayment Terms: The $10 million Second Advance must be prepaid by April 30, 2016, without penalty, unless specific conditions are met.
- Conditions to Avoid Prepayment: The Company must achieve clinical milestones for vepoloxamer and AIR001 by December 31, 2015, AND by April 30, 2016, either secure $15 million in net cash proceeds from partnerships/equity or demonstrate positive results in the Phase 3 EPIC study for sickle cell disease.
- Interest Payments: Monthly interest-only payments are required until June 1, 2016. This period may be extended to September 1, 2016, and potentially to March 1, 2017, contingent on positive EPIC results and no default events.
- Risk: Failure to meet the clinical or financing milestones by the specified dates triggers a mandatory prepayment obligation.
Investor Verification Checklist
- Verify the current status of the Phase 3 EPIC clinical study for vepoloxamer.
- Confirm whether the Company has secured the $15 million in net cash proceeds required to avoid prepayment by April 30, 2016.
- Review the total outstanding debt balance and interest rate obligations under the amended agreement.
- Assess the dilution impact of the amended warrant covering 1,524,390 shares.